Delivery Order SPE2DB22D2214-SPE2DB24FS4WE
Award Date
5/14/24
Potential Completion Date
5/15/24
Potential Value
$32K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a specialty pharmaceutical product. The delivery order has a potential value of $1,577.28 and a completion date of February 28, 2024. This order is likely part of Amerisourcebergen Drug Corp's broader indefinite...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $7,148.05 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The contract has an ultimate completion date of March 25, 2024 and does not utilize any set-aside designation. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA valued up to $999,999,999.00 through December 31,...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The order is valued at $78,009.98 and has a firm fixed-price contract type with a completion date of June 5, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The $13,822.44 firm-fixed-price contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. Amerisourcebergen, a major pharmaceutical distribution company, is fulfilling this order through a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that it holds with DLA Troop Support Medical,...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a completion date of February 8, 2024 and a potential value of $1,577.28. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Additionally, Amerisourcebergen Drug Corp holds...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,684.96 and covers the delivery of HEPLISAV-B 20 MCG/0.5 ML syringes. The award has an ultimate completion date of January 23, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a firm fixed price of $7,097.76 and a period of performance through May 14, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The $3,943.20 award has a completion date of February 6, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor to DLA Troop Support Medical, supplying pharmaceuticals and medical supplies in...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a potential value of $2,365.92 and a completion date of February 29, 2024. This appears to be part of a larger indefinite delivery contract (IDC) between Amerisourcebergen Drug Corp and DLA, valued at up to...